Cargando…

A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis

BACKGROUND: Psoriasis is an inflammatory systemic disease with a chronic relapsing course. Methotrexate, a dihydrofolate reductase inhibitor, and Apremilast, an oral phosphodiesterase type 4 inhibitor, are currently the mainstay drugs in the treatment of psoriasis. AIMS AND OBJECTIVES: To compare th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srivastava, Divyanshu, Krishna, Arvind, David, Abhinav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564189/ https://www.ncbi.nlm.nih.gov/pubmed/37822410 http://dx.doi.org/10.4103/ijd.ijd_813_22

Ejemplares similares

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Comparative Effectiveness and Safety of Methotrexate Versus PUVA in Severe Chronic Stable Plaque Psoriasis
por: Banerjee, Saikat, et al.
Publicado: (2021)

Efficacy of Methotrexate in patients with plaque type psoriasis
por: Haider, Sabiqa, et al.
Publicado: (2014)

Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey
por: Fougerousse, Anne-Claire, et al.
Publicado: (2021)

Effects of methotrexate and etanercept treatment in moderate and severe psoriasis
por: Benites, Elizabeth, et al.
Publicado: (2022)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

Acute methotrexate toxicity presenting as ulcers in plaques of psoriasis vulgaris
por: Bhatnagar, Anuj, et al.
Publicado: (2015)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching‐adjusted indirect comparison
por: Bewley, A.P., et al.
Publicado: (2019)

Methotrexate Toxicity During Treatment of Chronic Plaque Psoriasis: A Case Report and Review of the Literature
por: Weidmann, Anja, et al.
Publicado: (2014)

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

Comparative Efficacy Study Combination of Oral Methotrexate and Prednisolone versus Oral Methotrexate in Patients with Lichen Planopilaris
por: Fatemi, Farahnaz, et al.
Publicado: (2022)

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
por: Van Voorhees, A.S., et al.
Publicado: (2021)

Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris
por: Morita, Akimichi, et al.
Publicado: (2022)

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
por: Zargaran, Marzieh, et al.
Publicado: (2021)

Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability
por: Manalo, Iviensan F, et al.
Publicado: (2015)

Evaluation of the Efficacy of Combined Therapy of Methotrexate and Etanercept versus Methotrexate as a Mono-Therapy
por: Rexhepi, Sylejman, et al.
Publicado: (2018)

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
por: Salem, Heba F., et al.
Publicado: (2022)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
por: Reich, K., et al.
Publicado: (2018)

Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials
por: West, Jonathan, et al.
Publicado: (2016)

Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis
por: Vena, Gino Antonio, et al.
Publicado: (2018)

Nail psoriasis treated with intralesional methotrexate infiltration
por: Duarte, Artur Antônio, et al.
Publicado: (2019)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment
por: Reich, K., et al.
Publicado: (2019)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
por: Reich, K., et al.
Publicado: (2016)

Correction: Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials
Publicado: (2016)

Comparative Study of Clinical Characteristics according to Therapeutic Efficacy and Drug Survival of Cyclosporine or Methotrexate in Psoriasis Vulgaris
por: Lee, Hyun Soo, et al.
Publicado: (2019)

Efficacy of Methotrexate on Pain Severity Reduction and Improvement of Quality of Life in Patients with Moderate to Severe Knee Osteoarthritis
por: Enteshari-Moghaddam, Afsaneh, et al.
Publicado: (2019)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Nitric Oxide Levels in Patients with Psoriasis Treated with Methotrexate
por: Tekin, Nilgun Solak, et al.
Publicado: (2006)

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
por: Warren, RB, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v9o6qvsm1kk95fcksr7bualchr